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A bdominal aortic aneurysm (AAA) is a perma-nent dilation of the abdominal aorta with an 
onset of symptoms that is often insidious until the overt 
manifestation of rupture.  The prevalence of AAA 
increases with age.  AAA is uncommon in persons 
younger than 50 years; however,  12.5% of men and 
5.2% of women 74-84 years of age have AAA [1].  It 
accounts for approximately 11,000 deaths each year in 
the United States,  with mortality rates from ruptured 
AAAs reaching up to 90% [2].  In 2014,  AAA and aor-
tic dissection were the ninth leading cause of death in 
the Population Survey Report from the Ministry of 
Health,  Labor and Welfare in Japan.  The major risk 
factors for aortic aneurysm are age older than 65 years,  
male gender,  family history,  and smoking [3].  In addi-
tion to these risk factors,  age related-diseases such as 
hypertension,  ischemic heart diseases,  and chronic 
kidney diseases,  but not diabetes mellitus,  are also 
related to the high prevalence of AAA in Japan and 
Western countries [4].
The management of AAA varies according to AAA 
size. Open and endovascular surgical repairs are ini-
tially indicated in patients with large AAAs (> 5.5 cm) 
to prevent aneurysms from rupturing [3].  Since AAA is 
common in the elderly,  the risks of postoperative com-
plications should be considered.  Frailty is also common 
in elderly people.  The prevalence of frailty increases 
with coexisting cardiovascular diseases [5].  In addition 
to the classical risk factors for frailty,  including age,  
female gender,  cardiac failure,  chronic obstructive pul-
monary disease,  renal impairment,  cerebrovascular 
disease,  peripheral artery disease,  ischemic heart dis-
ease,  and diabetes mellitus,  a prospective study from 
over 200 American and Canadian hospitals revealed 
that evaluation for frailty should be required in the risk 
assessment of AAA [6].  Endovascular repair is more 
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reasonable than open repair in patients with cardiopul-
monary or other associated diseases.  In particular,  
endovascular therapy is a useful option in patients who 
are unable to tolerate open surgery,  because it is a min-
imally invasive therapy.  However,  endovascular ther-
apy is unsuitable for patients with anatomical problems 
involving the neck angles and approach.  Moreover,  graft 
complications and re-interventions due to various types 
of end-leaks occur more often in patients with endovas-
cular therapy (9-10%) [7].  Thus,  there are both advan-
tages and drawbacks to the current surgical options.
Given the limitations for surgical therapy,  several 
medical options have been studied for the management 
of small aortic aneurysms,  with the goal of slowing 
aneurysmal growth and preventing rupture.  Aneurysmal 
growth and rupture are considered to be partially due to 
vascular inflammation,  mechanical stress and matrix 
metalloproteinase activities.
Good management of blood pressure reduces pro-
gression and rupture of AAAs.  It has been suggested 
that β blockers could correct excessive extracellular matrix 
remodeling,  in addition to lowering blood pressure [8].  
In one clinical study,  β blockers were shown to reduce 
perioperative mortality from AAAs.  However,  pro-
pranolol was reported to have no significant effect in terms 
of limiting AAA growth in three clinical trials,  all of 
which reported poor patient compliance with treatment 
[9 , 10].  Moreover,  angiotensin II has been shown to 
promote inflammation,  matrix remodeling and hyper-
tension,  resulting in AAA formation and ruptures in 
many animal studies.  Blocking angiotensin II with 
angiotensin II receptor blockers and angiotensin con-
verting enzyme inhibitors were expected to have a ben-
eficial effect on AAA growth and rupture.  However,  
clinical trials have failed to show a favorable effect of 
renin-angiotensin system blockages [11 , 12].  Thus,  the 
effect of anti-hypertensive drugs,  including β blockers 
and renin-angiotensin system inhibitors,  on AAA 
enlargement has not been clarified.
Statins attenuated the development and growth of 
experimental AAA through anti-inflammatory and 
anti-oxidative stress effects; however,  several clinical 
studies failed to show that they affected AAA enlarge-
ment and rupture.
Doxycycline,  a broad inhibitor of matrix-metallo-
proteinase,  was successfully demonstrated to slow AAA 
growth in a small human study [13].  However,  it failed 
to show a significant effect on the AAA growth in phase 
II and double-blind control studies [14 , 15].
Cyclosporine,  an inhibitor of cyclophilin A,  was also 
expected to suppress the development and progression 
of AAA by inhibiting inflammatory cell recruitment and 
matrix metalloproteinase activities in animal studies 
[16].  Short-course administration of cyclosporine A 
was shown to stabilize the diameter of formed AAA by 
upregulating TGF-β1 in animal models; however,  the 
effect and usage of cyclosporin on human AAA and is 
still under investigation.
Most AAAs contain a large volume of intraluminal 
thrombus,  and the volume of this thrombus has been 
correlated with AAA growth.  Anti-platelet drugs were 
expected to reduce inflammatory cytokines and matrix- 
degrading enzymes by reducing thrombus volume.  Only 
a few studies showed significant positive effects of anti- 
platelet drugs such as aspirin or P2Y12 inhibitors on the 
development and progression of AAAs,  or death from 
AAAs.  Clinical trials examining the efficacy of the anti- 
platelet agent ticagrelor in limiting AAA growth are 
currently ongoing.  Cilostazol inhibits platelet aggrega-
tion by mechanisms different than aspirin or P2Y12 
inhibitors.  Cilostazol has been reported to have some 
favorable effects in the field of cerebrovascular diseases 
through its peritrophic effects [17].  We previously 
demonstrated the potential ability of cilostazol,  a PDE-
III inhibitor,  on AAA development through its anti-in-
flammatory effect [18].  Cilostazol is already used in 
clinical practice for patients with peripheral artery dis-
eases and stroke.  Since patients with AAA often have 
many vascular complications,  including coronary artery 
disease,  myocardial infarction,  and peripheral artery 
disease,  our findings may suggest a favorable option for 
AAA treatment.
Development of minimally invasive treatment includ-
ing drug therapies is very desirable for AAA treatment,  
especially for elderly people and patients with many 
complications.  Over the last decade,  emerging evidence 
has highlighted several mechanistic insights into AAA 
growth and rupture using animal models,  but transla-
tional studies from bench to bedside are still lacking.  
Further large clinical trials are necessary to explore new 
promising therapies.
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